BCL2 and pachyonychia congenita: While combination of targeted therapies with chemotherapeutic drugs has been tested against PC, this is the first study, to the best of our knowledge, to report that priming of tumor cells with highly specific Bcl-2 inhibitor enhances cytotoxic activity armed ATC.